Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | DGKA | P23743 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7290192 | 1.00 | TSHR (0.62) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL89184 | 1.00 | TSHR (0.62) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL1686744 | 1.00 | TSHR (0.62) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL7946850 | 1.00 | TSHR (0.62) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL362356 | 1.00 | TSHR (0.62) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL20398941 | 1.00 | TSHR (0.62) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL1306604 | 0.98 | TSHR (0.59) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL3964566 | 0.92 | NR1I2 (0.59) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL23595590 | 0.86 | ALOX15 (0.80) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 | |
| SCHEMBL15457464 | 0.86 | ALOX15 (0.80) | TSHRALDH1A1CYP3A4ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135059-A1 | COMPOSITIONS COMPRISING FRAGRANCE MATERIALS | THE PROCTER & GAMBLE COMPANY | 2025-05-01 | — | — | US | disclosed |
| US-8129552-B2 | for transporting drugs or as gene transport vehicles, as solubilizers for drugs of low solubility in water, and themselves as active ingredients against diseases such as cancer or leishmaniosis; (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129552-B2 | for transporting drugs or as gene transport vehicles, as solubilizers for drugs of low solubility in water, and themselves as active ingredients against diseases such as cancer or leishmaniosis; (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7649103-B2 | Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field | MEDESTEA RESEARCH AND PRODUCTION S.R.L. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-7649103-B2 | Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field | MEDESTEA RESEARCH AND PRODUCTION S.R.L. (IT) | 2010-01-19 | — | — | US | disclosed |
| US-7649103-B2 | Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field | MEDESTEA RESEARCH AND PRODUCTION S.R.L. (IT) | 2010-01-19 | — | — | US | disclosed |
| EP-1515714-B1 | LONG CHAIN UNSATURATED OXYGENATED COMPOUNDS AND THEIR USE IN THE THERAPEUTICAL, COSMETIC AND NUTRACEUTICAL FIELD | MEDESTEA RES & PRODUCTION S P (IT) | 2009-08-12 | — | — | EP | disclosed |
| EP-1515714-B1 | LONG CHAIN UNSATURATED OXYGENATED COMPOUNDS AND THEIR USE IN THE THERAPEUTICAL, COSMETIC AND NUTRACEUTICAL FIELD | MEDESTEA RES & PRODUCTION S P (IT) | 2009-08-12 | — | — | EP | disclosed |
| US-20080214849-A1 | PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214849-A1 | PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSHAFTEN E.V. (DE) | 2008-09-04 | — | — | US | disclosed |
| US-5147857-A | Enzyme inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1992-09-15 | — | — | US | disclosed |
| EP-0501280-A2 | Renin-inhibiting peptide analogues | MERCK PATENT GmbH (DE) | 1992-09-02 | — | — | EP | disclosed |
| EP-0499080-A2 | Aminoacid derivatibes | MERCK PATENT GmbH (DE) | 1992-08-19 | — | — | EP | disclosed |
| EP-0481311-A2 | Aminoacid derivatives | MERCK PATENT GmbH (DE) | 1992-04-22 | — | — | EP | disclosed |
| EP-0474008-A1 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1992-03-11 | — | — | EP | disclosed |
| EP-0464517-A2 | Amino acid derivatives with renin inhibiting activity | MERCK PATENT GmbH (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214849-A1 | PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS | PHOSPHO1, PLTP, SGMS1 | TSHR 4438/4885ALDH1A1 4394/4885CYP3A4 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.